Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.

ABSTRACT:

Purpose

This article reviews the essential clinical trials that have led to these immunotherapy approvals and explores the use of predictive biomarkers, such as PD-L1 expression and MSI status, to identify patients who are most likely to benefit from immunotherapies.

Methods

This case review series describe findings from different clinical trials and contribute to the evolving understanding of the role of CPIs in managing advanced gastroesophageal cancers and may lead to improved treatment options and patient outcomes. Ongoing clinical trials also hold promise for expanding treatment options and improving patient outcomes in the future.

Methods

The systematic review followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses

SUBMITTER: Karim F 

PROVIDER: S-EPMC10452271 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature